西利宾胺预防HBVM阳性患者结核性药物肝损害的临床研究  

A Clinical Study of Silibinin-N-Methy lglucamine on Preventing Hepatic Damage of HBVM Positive Patients Induced by Antituberculos is Medicament

作　　者：田磊[1] 白敏[1] 李安娜[1] 张建树[1] 杨令果[1] 

机构地区：[1]解放军第91医院传染结核科,山东兖州272100

出　　处：《临床军医杂志》2003年第2期19-21,共3页Clinical Journal of Medical Officers

摘　　要：目的　探讨西利宾胺对HBVM阳性患者的结核性药物肝损害的预防效果。方法　 14 5例HBVM阳性的肺结核患者随机分观察组和对照组 ,均应用含“HR”方案抗结核化疗 ,观察组同时加用西利宾胺预防药物性肝损害。结果　药物性肝损害发生率观察组为 2 0 .3% ,对照组为 4 7.9% ,两组比较差异非常显著 (P <0 .0 1)。抗结核化疗中断发生率观察组为 13.5 %。对照组为 35 .2 % ,差异非常显著 (P <0 .0 1)。重新调整化疗方案的发生率观察组为 8.1% ,对照组为 2 5 .4 % ,两者比较差异显著 (P <0 .0 5 )。结论　西利宾胺可显著降低HBVM阳性患者的结核性药物性肝损害的发生率 。Objective To probe into the preventive efficacy of Silibinin N Methylglucamine on the liver damage caused by antituberculosis medicament.Methods 145 pulmonary tuberculosis patients were classified at random into two groups,experiment group and control group.Both groups were administered chernotherapy containing the 'HR' scheme to treat pulmonary tuberculosis,and additionally,the Patients in the experiment group also took Silibinin N Methylglucamine.Results The incdence rate of medicamentous liver damage in the experiment group was 20.3%,and the control group 47.9%.The difference was very significant( P <0.01).The incidence rete of interrupting treatment in the experiment group was 13.5%,and the control group 35.2%.The difference was very significant too ( P <0.01).8.1% of cases in the experiment group had adjusted the antituberclosis medicament,but in the control group the rate was 25.4%,indicaing a significant difference ( P <0.05).Conclusion Silibinin N Methylglucamine can obviously decrease the incidence rate of liver damage of HBVM positive patiens induced by antituberculosis medicament,and decrese or prevent the irregular chemotherapy that results from the liver damage caused by antituberculosis medicament.

关 键 词：西利宾胺 预防 HBVM阳性 结核性药物肝损害 抗结核化疗 乙型肝炎病毒感染 

分 类 号：R525[医药卫生—内科学] R512.62[医药卫生—临床医学]